University of Ioannina, Medical School, Rheumatology Clinic, Department of Internal Medicine, Ioannina, Greece.
Expert Opin Biol Ther. 2012 Dec;12(12):1679-86. doi: 10.1517/14712598.2012.721771. Epub 2012 Sep 6.
Adalimumab (ADA), a fully human monoclonal antibody against TNF-α is indicated for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and psoriasis. In RA, it may be prescribed in combination with methotrexate or other disease-modifying antirheumatic drugs or as monotherapy. Studies comparing ADA with other TNF-α inhibitors are limited and are based mainly on meta-analyses of randomised controlled trials and large observational cohorts. In this study, the effectiveness and safety of ADA is compared with that of etanercept and infliximab.
阿达木单抗（ADA）是一种针对 TNF-α 的全人源单克隆抗体，用于治疗类风湿关节炎（RA）、银屑病关节炎、强直性脊柱炎、幼年特发性关节炎、克罗恩病、溃疡性结肠炎和银屑病。在 RA 中，它可能与甲氨蝶呤或其他疾病修正抗风湿药物联合使用，或作为单药治疗。比较 ADA 与其他 TNF-α 抑制剂的研究有限，主要基于随机对照试验和大型观察队列的荟萃分析。在这项研究中，阿达木单抗的有效性和安全性与依那西普和英夫利昔单抗进行了比较。
